From ‘facilitator’ to ‘regulator’: How Rajeev Raghuvanshi is fixing the gaps in pharma industry

Rajeev Singh Raghuvanshi, the Drug Controller General of India; image credit: Vikas Dandekar


The pharmaceutical industry, and the central drug regulatory agency, faced a severe reputation crisis following the deaths of 70 children in Gambia due to contaminated cough syrups in 2022. A few months later, Rajeev Raghuvanshi took over as the Drug Controller General of India and is currently driving a transformational change. Can he set a high bar for product quality?

For a moment, one might mistake it for a corporate office. Shiny cars pulling over. Executives in dapper suits sauntering in. That’s how the FDA Bhawan — the headquarters of India’s apex drug regulatory agency, the Central Drug Standard Control Organisation (CDSCO) — in Delhi’s bustling ITO area always looked. The building is at the heart of every critical decision that impacts the Indian pharmaceutical industry – from launch of new drugs to

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *